Benjamin Solomon, MBBS, PhD, discusses the intracranial responses observed in the CROWN trial of lorlatinib versus crizotinib in patients with ALK-positive non–small cell lung cancer.
Benjamin Solomon, MBBS, PhD, consultant medical oncologist, professor, group leader, Molecular Therapeutics and Biomarkers Laboratory, Research Division, Peter MacCallum Cancer Center, discusses the intracranial responses observed in the CROWN trial of lorlatinib (Lorbrena) versus crizotinib (Xalkori) in patients with ALK-positive non–small cell lung cancer (NSCLC).
The intracranial activity seen with lorlatinib was 1 of the most important findings in this phase 3 study, according to Solomon. All the patients on the trial received baseline MRIs and serial assessments of disease in the brain with subsequent MRI scans which were independently reviewed.
In patients with measurable brain metastases, the intracranial objective response rate by independent review was 82% with lorlatinib compared with 23% with crizotinib. The intracranial complete response rate was 71% with lorlatinib in these patients with ALK-positive NSCLC.
The time to intracranial progression showed a hazard ratio of 0.70. Solomon says this is a remarkable result and speaks to the ability of lorlatinib in its ability to not only delay progression of existing metastases, but also potentially prevent the development of new brain metastases.
Peritoneal RFS May Be a Stronger Predictor of OS in CRC Peritoneal Metastasis
March 27th 2024In an interview with Targeted Oncology, Muhammad Talha Waheed, MBBS, discussed research on the reliability of using recurrence-free survival as an efficacy end point for trials evaluating patients with colorectal cancer peritoneal metastasis.
Read More
Integrating New Therapies With Autologous Stem Cell Transplant in Myeloma
March 26th 2024Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed how the role of autologous stem cell transplant is evolving in the myeloma treatment landscape with the emergence of CAR T-cell therapies and bispecifics.
Read More